{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T22:19:38Z","timestamp":1791670778405,"version":"4.3.4"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T00:00:00Z","timestamp":1756512000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T00:00:00Z","timestamp":1756512000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2025,11,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pancreatic ductal adenocarcinoma (PDAC) presents an urgent challenge that necessitates improved early risk identification. We investigated the association between predictors of PDAC present at least two years before diagnosis and PDAC occurence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This case-control study used electronic health records from The Health Improvement Network Database (UK). Cases (10,575) were matched with controls (105,750) in a 1:10 ratio by gender, age, follow-up duration, and year of inclusion in the database. Variables included clinical features, comorbidities and blood result abnormalities, reported at least 2 years before PDAC diagnosis or equivalent timeframe for controls. Conditional logistic regression model with backward estimated odds ratios (OR) and 95% confidence interval (CI).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Electronic health records of cases reported higher prevalence of alcohol intake, cigarette smoking, dyslipidemia, increased blood pressure, and diabetes of more than four years\u2019 duration. Independent risk factors included pancreatic cysts (OR\u2009=\u20094.39), pancreatitis (OR\u2009=\u20092.16), dyslipidemia (OR\u2009=\u20091.50), smoking (OR\u2009=\u20091.09), and alcohol intake (OR\u2009=\u20091.09). Laboratory markers associated with higher risk included elevated alkaline phosphatase (OR\u2009=\u20093.21), bilirubin (OR\u2009=\u20092.48), alanine aminotransferase (OR\u2009=\u20091.76), erythrocyte sedimentation rate (OR\u2009=\u20091.27), and decreased albumin (OR\u2009=\u20091.54).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Primary care electronic records can identify individuals at medium-term increased risk of PDAC, thus raises the opportunity to develop early detection models and address modifiable factors.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41416-025-03172-5","type":"journal-article","created":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T15:29:23Z","timestamp":1756567763000},"page":"1317-1325","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Identifying health conditions associated with an increased risk of pancreatic ductal adenocarcinoma at medium term in nationwide electronic health records of primary care physicians"],"prefix":"10.1038","volume":"133","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7906-0991","authenticated-orcid":false,"given":"Elie","family":"Rassy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2106-9165","authenticated-orcid":false,"given":"Suzette","family":"Delaloge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yannis","family":"Slaouti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Pudlarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9ranger","family":"Lekens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3708-4909","authenticated-orcid":false,"given":"Alice","family":"Boil\u00e8ve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6963-2968","authenticated-orcid":false,"given":"Stefan","family":"Michiels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Karimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,30]]},"reference":[{"key":"3172_CR1","first-page":"1","volume":"2","author":"J Kleeff","year":"2016","unstructured":"Kleeff J, Korc M, Apte M, La Vecchia C, Johnson CD, Biankin AV, et al. Pancreatic cancer. Nat Rev Dis Prim. 2016;2:1\u201322.","journal-title":"Nat Rev Dis Prim"},{"key":"3172_CR2","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"3172_CR3","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/S2468-1253(19)30347-4","volume":"4","author":"A Pourshams","year":"2019","unstructured":"Pourshams A, Sepanlou SG, Ikuta KS, Bisignano C, Safiri S, Roshandel G, et al. The global, regional, and national burden of pancreatic cancer and its attributable risk factors in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2019;4:934\u201347.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"3172_CR4","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s41575-021-00457-x","volume":"18","author":"AP Klein","year":"2021","unstructured":"Klein AP. Pancreatic cancer epidemiology: understanding the role of lifestyle and inherited risk factors. Nat Rev Gastroenterol Hepatol. 2021;18:493\u2013502.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"3172_CR5","doi-asserted-by":"publisher","first-page":"v56","DOI":"10.1093\/annonc\/mdv295","volume":"26","author":"M Ducreux","year":"2015","unstructured":"Ducreux M, Cuhna ASA, Caramella C, Hollebecque A, Burtin P, Go\u00e9r\u00e9 D, et al. Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up\u2020. Ann Oncol. 2015;26:v56\u201368.","journal-title":"Ann Oncol"},{"key":"3172_CR6","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1056\/NEJMoa032295","volume":"350","author":"JP Neoptolemos","year":"2004","unstructured":"Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004;350:1200\u201310.","journal-title":"N Engl J Med"},{"key":"3172_CR7","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1001\/jama.2013.279201","volume":"310","author":"H Oettle","year":"2013","unstructured":"Oettle H, Neuhaus P, Hochhaus A, Hartmann JT, Gellert K, Ridwelski K, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA. 2013;310:1473\u201381.","journal-title":"JAMA"},{"key":"3172_CR8","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1056\/NEJMoa1809775","volume":"379","author":"T Conroy","year":"2018","unstructured":"Conroy T, Hammel P, Hebbar M, Ben Abdelghani M, Wei AC, Raoul JL, et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med. 2018;379:2395\u2013406.","journal-title":"N Engl J Med"},{"key":"3172_CR9","doi-asserted-by":"publisher","unstructured":"Conroy T, Castan F, Lopez A, Turpin A, Ben Abdelghani M, Wei AC, et al. Five-year outcomes of FOLFIRINOX vs gemcitabine as adjuvant therapy for pancreatic cancer: a randomized clinical trial. JAMA Oncol [Internet]. 2022 [cited 16 Nov 2022] https:\/\/doi.org\/10.1001\/jamaoncol.2022.3829","DOI":"10.1001\/jamaoncol.2022.3829"},{"key":"3172_CR10","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1001\/jama.297.3.267","volume":"297","author":"H Oettle","year":"2007","unstructured":"Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancera randomized controlled trial. JAMA 2007;297:267\u201377.","journal-title":"JAMA"},{"key":"3172_CR11","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1001\/jama.2010.1275","volume":"304","author":"JP Neoptolemos","year":"2010","unstructured":"Neoptolemos JP, Stocken DD, Bassi C, Ghaneh P, Cunningham D, Goldstein D, et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA. 2010;304:1073\u201381.","journal-title":"JAMA"},{"key":"3172_CR12","doi-asserted-by":"publisher","first-page":"2913","DOI":"10.1158\/0008-5472.CAN-14-0155","volume":"74","author":"L Rahib","year":"2014","unstructured":"Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74:2913\u201321.","journal-title":"Cancer Res"},{"key":"3172_CR13","doi-asserted-by":"publisher","first-page":"e72311","DOI":"10.1371\/journal.pone.0072311","volume":"8","author":"AP Klein","year":"2013","unstructured":"Klein AP, Lindstr\u00f6m S, Mendelsohn JB, Steplowski E, Arslan AA, Bueno-de-Mesquita HB, et al. An absolute risk model to identify individuals at elevated risk for pancreatic cancer in the general population. PLOS ONE. 2013;8:e72311.","journal-title":"PLOS ONE"},{"key":"3172_CR14","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1053\/j.gastro.2016.11.046","volume":"152","author":"B Boursi","year":"2017","unstructured":"Boursi B, Finkelman B, Giantonio BJ, Haynes K, Rustgi AK, Rhim AD, et al. A clinical prediction model to assess risk for pancreatic cancer among patients with new-onset diabetes. Gastroenterology. 2017;152:840\u201350.e3.","journal-title":"Gastroenterology"},{"key":"3172_CR15","doi-asserted-by":"publisher","first-page":"6317","DOI":"10.2147\/CMAR.S180791","volume":"10","author":"MH Hsieh","year":"2018","unstructured":"Hsieh MH, Sun LM, Lin CL, Hsieh MJ, Hsu CY, Kao CH. Development of a prediction model for pancreatic cancer in patients with type 2 diabetes using logistic regression and artificial neural network models. Cancer Manag Res 2018;10:6317\u201324.","journal-title":"Cancer Manag Res"},{"key":"3172_CR16","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1053\/j.gastro.2018.05.023","volume":"155","author":"A Sharma","year":"2018","unstructured":"Sharma A, Kandlakunta H, Nagpal SJS, Feng Z, Hoos W, Petersen GM, et al. Model to determine risk of pancreatic cancer in patients with new-onset diabetes. Gastroenterology. 2018;155:730\u20139.e3.","journal-title":"Gastroenterology"},{"key":"3172_CR17","doi-asserted-by":"crossref","unstructured":"Muhammad W, Hart GR, Nartowt B, Farrell JJ, Johung K, Liang Y, et al. Pancreatic cancer prediction through an artificial neural network. Front Artif Intell. 2019;2.","DOI":"10.3389\/frai.2019.00002"},{"key":"3172_CR18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0218580","volume":"14","author":"A Baecker","year":"2019","unstructured":"Baecker A, Kim S, Risch HA, Nuckols TK, Wu BU, Hendifar AE, et al. Do changes in health reveal the possibility of undiagnosed pancreatic cancer? Development of a risk-prediction model based on healthcare claims data. PLOS ONE. 2019;14:e0218580.","journal-title":"PLOS ONE"},{"key":"3172_CR19","doi-asserted-by":"publisher","first-page":"e202948","DOI":"10.1001\/jamaoncol.2020.2948","volume":"6","author":"C Yuan","year":"2020","unstructured":"Yuan C, Babic A, Khalaf N, Nowak JA, Brais LK, Rubinson DA, et al. Diabetes, weight change, and pancreatic cancer risk. JAMA Oncol. 2020;6:e202948.","journal-title":"JAMA Oncol"},{"key":"3172_CR20","first-page":"19","volume":"143","author":"L Appelbaum","year":"2021","unstructured":"Appelbaum L, Cambronero JP, Stevens JP, Horng S, Pollick K, Silva G, et al. Development and validation of a pancreatic cancer risk model for the general population using electronic health records: an observational study. Eur J Cancer Oxf Engl 1990. 2021;143:19\u201330.","journal-title":"Eur J Cancer Oxf Engl 1990"},{"key":"3172_CR21","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1001\/jama.2019.10232","volume":"322","author":"DK Owens","year":"2019","unstructured":"US Preventive Services Task Force, Owens DK, Davidson KW, Krist AH, Barry MJ, Cabana M, et al. Screening for pancreatic cancer: US Preventive Services Task Force Reaffirmation Recommendation Statement. JAMA 2019;322:438\u201344.","journal-title":"JAMA"},{"key":"3172_CR22","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1002\/cac2.12204","volume":"41","author":"J Yang","year":"2021","unstructured":"Yang J, Xu R, Wang C, Qiu J, Ren B, You L. Early screening and diagnosis strategies of pancreatic cancer: a comprehensive review. Cancer Commun. 2021;41:1257\u201374.","journal-title":"Cancer Commun"},{"key":"3172_CR23","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1001\/jama.2019.6190","volume":"322","author":"NB Henrikson","year":"2019","unstructured":"Henrikson NB, Aiello Bowles EJ, Blasi PR, Morrison CC, Nguyen M, Pillarisetty VG, et al. Screening for pancreatic cancer: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2019;322:445\u201354.","journal-title":"JAMA"},{"key":"3172_CR24","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1136\/gutjnl-2019-319352","volume":"69","author":"M Goggins","year":"2020","unstructured":"Goggins M, Overbeek KA, Brand R, Syngal S, Del Chiaro M, Bartsch DK, et al. Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium. Gut. 2020;69:7\u201317.","journal-title":"Gut"},{"key":"3172_CR25","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1093\/jamia\/ocw042","volume":"24","author":"BA Goldstein","year":"2017","unstructured":"Goldstein BA, Navar AM, Pencina MJ, Ioannidis JPA. Opportunities and challenges in developing risk prediction models with electronic health records data: a systematic review. J Am Med Inf Assoc. 2017;24:198\u2013208.","journal-title":"J Am Med Inf Assoc"},{"key":"3172_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-021-01416-5","volume":"21","author":"MA Gianfrancesco","year":"2021","unstructured":"Gianfrancesco MA, Goldstein ND. A narrative review on the validity of electronic health record-based research in epidemiology. BMC Med Res Methodol. 2021;21:234.","journal-title":"BMC Med Res Methodol"},{"key":"3172_CR27","doi-asserted-by":"publisher","first-page":"e169","DOI":"10.1016\/S2589-7500(21)00275-2","volume":"4","author":"T Nedelec","year":"2022","unstructured":"Nedelec T, Couvy-Duchesne B, Monnet F, Daly T, Ansart M, Gantzer L, et al. Identifying health conditions associated with Alzheimer\u2019s disease up to 15 years before diagnosis: an agnostic study of French and British health records. Lancet Digit Health. 2022;4:e169\u201378.","journal-title":"Lancet Digit Health"},{"key":"3172_CR28","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.44849","volume":"5","author":"E Rassy","year":"2022","unstructured":"Rassy E, Bardet A, Bougacha O, Gantzer L, Lekens B, Delaloge S, et al. Association of adherence to endocrine therapy among patients with breast cancer and potential drug-drug interactions. JAMA Netw Open. 2022;5:e2244849.","journal-title":"JAMA Netw Open"},{"key":"3172_CR29","doi-asserted-by":"publisher","first-page":"781","DOI":"10.2147\/COPD.S153655","volume":"13","author":"JR Hurst","year":"2018","unstructured":"Hurst JR, Dilleen M, Morris K, Hills S, Emir B, Jones R. Factors influencing treatment escalation from long-acting muscarinic antagonist monotherapy to triple therapy in patients with COPD: a retrospective THIN-database analysis. Int J Chron Obstruct Pulmon Dis. 2018;13:781\u201392.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"3172_CR30","doi-asserted-by":"publisher","first-page":"e001585","DOI":"10.1136\/bmjresp-2022-001585","volume":"10","author":"G Deslee","year":"2023","unstructured":"Deslee G, Fabry-Vendrand C, Poccardi N, Thabut G, Eteve Pitsaer C, Coriat A, et al. Use and persistence of single and multiple inhaler triple therapy prescribed for patients with COPD in France: a retrospective study on THIN database (OPTI study). BMJ Open Respir Res. 2023;10:e001585.","journal-title":"BMJ Open Respir Res"},{"key":"3172_CR31","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1002\/pds.1335","volume":"16","author":"JD Lewis","year":"2007","unstructured":"Lewis JD, Schinnar R, Bilker WB, Wang X, Strom BL. Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research. Pharmacoepidemiol Drug Saf. 2007;16:393\u2013401.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"3172_CR32","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s00198-009-1003-1","volume":"21","author":"C Cooper","year":"2010","unstructured":"Cooper C, Steinbuch M, Stevenson R, Miday R, Watts NB. The epidemiology of osteonecrosis: findings from the GPRD and THIN databases in the UK. Osteoporos Int. 2010;21:569\u201377.","journal-title":"Osteoporos Int"},{"key":"3172_CR33","doi-asserted-by":"publisher","first-page":"e881","DOI":"10.3399\/bjgp17X693485","volume":"67","author":"S Finnikin","year":"2017","unstructured":"Finnikin S, Ryan R, Marshall T. Statin initiations and QRISK2 scoring in UK general practice: a THIN database study. Br J Gen Pract. 2017;67:e881\u20137.","journal-title":"Br J Gen Pract"},{"key":"3172_CR34","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1177\/0269881118780011","volume":"32","author":"DP Osborn","year":"2018","unstructured":"Osborn DP, Petersen I, Beckley N, Walters K, Nazareth I, Hayes J. Weight change over two years in people prescribed olanzapine, quetiapine and risperidone in UK primary care: Cohort study in THIN, a UK primary care database. J Psychopharmacol. 2018;32:1098\u2013103.","journal-title":"J Psychopharmacol"},{"key":"3172_CR35","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s40264-012-0009-3","volume":"36","author":"X Zhou","year":"2013","unstructured":"Zhou X, Murugesan S, Bhullar H, Liu Q, Cai B, Wentworth C, et al. An evaluation of the THIN database in the OMOP common data model for active drug safety surveillance. Drug Saf. 2013;36:119\u201334.","journal-title":"Drug Saf"},{"key":"3172_CR36","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/j.ajhg.2020.08.025","volume":"107","author":"LG Fritsche","year":"2020","unstructured":"Fritsche LG, Patil S, Beesley LJ, VandeHaar P, Salvatore M, Ma Y, et al. Cancer PRSweb: an online repository with polygenic risk scores for major cancer traits and their evaluation in two independent biobanks. Am J Hum Genet. 2020;107:815\u201336.","journal-title":"Am J Hum Genet"},{"key":"3172_CR37","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1053\/j.gastro.2022.01.016","volume":"162","author":"S Sharma","year":"2022","unstructured":"Sharma S, Tapper WJ, Collins A, Hamady ZZR. Predicting pancreatic cancer in the UK biobank cohort using polygenic risk scores and diabetes mellitus. Gastroenterology. 2022;162:1665\u201374.e2.","journal-title":"Gastroenterology"},{"key":"3172_CR38","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1097\/MEG.0000000000002052","volume":"34","author":"B Boursi","year":"2022","unstructured":"Boursi B, Finkelman B, Giantonio BJ, Haynes K, Rustgi AK, Rhim AD, et al. A clinical prediction model to assess risk for pancreatic cancer among patients with prediabetes. Eur J Gastroenterol Hepatol. 2022;34:33\u20138.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"3172_CR39","doi-asserted-by":"crossref","unstructured":"Santos R, Coleman HG, Cairnduff V, Kunzmann AT. Clinical prediction models for pancreatic cancer in general and at-risk populations: a systematic review. Am J Gastroenterol. 2022;118, 26\u201340.","DOI":"10.14309\/ajg.0000000000002022"},{"key":"3172_CR40","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1093\/ije\/dyu240","volume":"44","author":"P Maisonneuve","year":"2015","unstructured":"Maisonneuve P, Lowenfels AB. Risk factors for pancreatic cancer: a summary review of meta-analytical studies. Int J Epidemiol. 2015;44:186\u201398.","journal-title":"Int J Epidemiol"},{"key":"3172_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-016-2241-1","volume":"16","author":"YT Wang","year":"2016","unstructured":"Wang YT, Gou YW, Jin WW, Xiao M, Fang HY. Association between alcohol intake and the risk of pancreatic cancer: a dose-response meta-analysis of cohort studies. BMC Cancer. 2016;16:212.","journal-title":"BMC Cancer"},{"key":"3172_CR42","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1093\/ije\/dyy082","volume":"47","author":"P Maisonneuve","year":"2018","unstructured":"Maisonneuve P, Lowenfels AB. Variation of the age at onset of pancreatic cancer according to tobacco smoking and family history. Int J Epidemiol. 2018;47:1357.","journal-title":"Int J Epidemiol"},{"key":"3172_CR43","first-page":"117","volume":"104","author":"A Lugo","year":"2018","unstructured":"Lugo A, Peveri G, Bosetti C, Bagnardi V, Crippa A, Orsini N, et al. Strong excess risk of pancreatic cancer for low frequency and duration of cigarette smoking: a comprehensive review and meta-analysis. Eur J Cancer Oxf Engl 1990. 2018;104:117\u201326.","journal-title":"Eur J Cancer Oxf Engl 1990"},{"key":"3172_CR44","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1158\/2159-8290.CD-15-1177","volume":"6","author":"J Incio","year":"2016","unstructured":"Incio J, Liu H, Suboj P, Chin SM, Chen IX, Pinter M, et al. Obesity-induced inflammation and desmoplasia promote pancreatic cancer progression and resistance to chemotherapy. Cancer Discov. 2016;6:852\u201369.","journal-title":"Cancer Discov"},{"key":"3172_CR45","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.coph.2009.06.011","volume":"9","author":"JB Greer","year":"2009","unstructured":"Greer JB, Whitcomb DC. Inflammation and pancreatic cancer: an evidence-based review. Curr Opin Pharm. 2009;9:411\u20138.","journal-title":"Curr Opin Pharm"},{"key":"3172_CR46","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1158\/1055-9965.EPI-07-0507","volume":"17","author":"A Berrington de Gonzalez","year":"2008","unstructured":"Berrington de Gonzalez A, Yun JE, Lee SY, Klein AP, Jee SH. Pancreatic cancer and factors associated with the insulin resistance syndrome in the Korean cancer prevention study. Cancer Epidemiol Biomark Prev. 2008;17:359\u201364.","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"3172_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-14856-w","volume":"12","author":"JH Park","year":"2022","unstructured":"Park JH, Hong JY, Han K, Kang W, Park JK. Increased risk of pancreatic cancer in individuals with non-alcoholic fatty liver disease. Sci Rep. 2022;12:10681.","journal-title":"Sci Rep"},{"key":"3172_CR48","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.2337\/db16-1477","volume":"66","author":"DK Andersen","year":"2017","unstructured":"Andersen DK, Korc M, Petersen GM, Eibl G, Li D, Rickels MR, et al. Diabetes, pancreatogenic diabetes, and pancreatic cancer. Diabetes. 2017;66:1103\u201310.","journal-title":"Diabetes"},{"key":"3172_CR49","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1007\/s11938-018-0197-8","volume":"16","author":"A Sharma","year":"2018","unstructured":"Sharma A, Chari ST. Pancreatic cancer and diabetes mellitus. Curr Treat Options Gastroenterol. 2018;16:466\u201378.","journal-title":"Curr Treat Options Gastroenterol"},{"key":"3172_CR50","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1038\/ajg.2017.218","volume":"112","author":"J Kirkeg\u00e5rd","year":"2017","unstructured":"Kirkeg\u00e5rd J, Mortensen FV, Cronin-Fenton D. Chronic pancreatitis and pancreatic cancer risk: a systematic review and meta-analysis. Am J Gastroenterol. 2017;112:1366\u201372.","journal-title":"Am J Gastroenterol"},{"key":"3172_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.canep.2019.101647","volume":"64","author":"J Kirkeg\u00e5rd","year":"2020","unstructured":"Kirkeg\u00e5rd J, Gaber C, Lund JL, Hinton SP, Ladekarl M, Heide-J\u00f8rgensen U, et al. Acute pancreatitis as an early marker of pancreatic cancer and cancer stage, treatment, and prognosis. Cancer Epidemiol. 2020;64:101647.","journal-title":"Cancer Epidemiol"},{"key":"3172_CR52","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1001\/jamaoncol.2023.5573","volume":"10","author":"L Wang","year":"2024","unstructured":"Wang L, Wang W, Kaelber DC, Xu R, Berger NA. GLP-1 receptor agonists and colorectal cancer risk in drug-naive patients with type 2 diabetes, with and without overweight\/obesity. JAMA Oncol. 2024;10:256\u20138.","journal-title":"JAMA Oncol"},{"key":"3172_CR53","doi-asserted-by":"crossref","unstructured":"Moll H, Frey E, Gerber P, Geidl B, Kaufmann M, Braun J, et al. GLP-1 receptor agonists for weight reduction in people living with obesity but without diabetes: a living benefit\u2013harm modelling study. EClinicalMedicine. 2024;1:73.","DOI":"10.1016\/j.eclinm.2024.102661"},{"key":"3172_CR54","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.14309\/ajg.0000000000002870","volume":"119","author":"AK Mishra","year":"2024","unstructured":"Mishra AK, Chong B, Arunachalam SP, Oberg AL, Majumder S. Machine learning models for pancreatic cancer risk prediction using electronic health record data\u2014a systematic review and assessment. J Am Coll Gastroenterol ACG. 2024;119:1466.","journal-title":"J Am Coll Gastroenterol ACG"}],"updated-by":[{"DOI":"10.1038\/s41416-026-03597-6","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000}}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03172-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03172-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03172-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T07:03:48Z","timestamp":1788246228000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03172-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,30]]},"references-count":54,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,11,16]]}},"alternative-id":["3172"],"URL":"https:\/\/doi.org\/10.1038\/s41416-025-03172-5","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,30]]},"assertion":[{"value":"27 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2026","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: In this article the author name has been corrected from \u2018Mariam Karimi\u2019 to \u2018Maryam Karimi\u2019.","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2026","order":9,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":10,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41416-026-03597-6","URL":"https:\/\/doi.org\/10.1038\/s41416-026-03597-6","order":12,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"ER reports grants (institutional) from Gilead and Menarini; travel, accommodations, and expenses fees from Pfizer, Roche, Mundipharma, Eli Lilly, Gilead, Novartis and Menarini; honoraria (institutional) for lectures, presentations, consultancy from Eli Lilly, Seagen, Novartis, Astrazeneca, and Menarini; all outside the scope of the submitted work. SD: Consulting or Advisory Role: AstraZeneca, Research Funding: AstraZeneca (Inst), Pfizer (Inst), Roche\/Genentech (Inst), Puma (Inst), Eli Lilly (Inst), Novartis (Inst), Sanofi (Inst). Travel, Accommodations, Expenses: Pfizer, AstraZeneca, Roche. YS and BL are employees of Cegedim. TP: Travel and accommodation fees from Servier and Viatris outside the submitted work. AB: Consulting or Advisory Role, Travel, Accommodations, Expenses: Mercks, Viatris, Ipsen, Servier. SM reports personal fees from Scientific Committee Study member to Roche, Data and safety monitoring member of clinical trials: IQVIA, Kedrion, Biophytis, Servier, Yuhan, all outside the scope of the submitted work. MK: None relevant to this study.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"THIN\u00ae comprises electronic medical records compliant with the European General Data Protection Regulations (GDPR). This study was examined and approved by THIN\u00ae Scientific Review Committee (protocol number 20 002 R1).","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"This is a retrospective data of THIN\u00ae comprises electronic medical records compliant with the European general data protection regulations (GDPR). A consent to publish this manuscript was not required.","order":3,"name":"Ethics","label":"Consent to publish","group":{"name":"EthicsHeading","label":"Ethics"}}]}}